Tri Locum Partners’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-33,750
| Closed | -$932K | – | 79 |
|
|
2023
Q2 | $932K | Sell |
33,750
-99,702
| -75% | -$2.75M | 0.35% | 38 |
|
|
2023
Q1 | $3.07M | Buy |
+133,452
| New | +$3.07M | 0.93% | 32 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 82 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 55 |
|
|
2022
Q2 | – | Sell |
-769,250
| Closed | -$18.2M | – | 58 |
|
|
2022
Q1 | $18.2M | Buy |
769,250
+455,321
| +145% | +$10.8M | 7.12% | 2 |
|
|
2021
Q4 | $10.7M | Buy |
+313,929
| New | +$10.7M | 4.23% | 9 |
|
|
2021
Q3 | – | Sell |
-341,650
| Closed | -$15.3M | – | 38 |
|
|
2021
Q2 | $15.3M | Buy |
341,650
+84,564
| +33% | +$3.8M | 5.02% | 6 |
|
|
2021
Q1 | $6.66M | Sell |
257,086
-2,197
| -0.8% | -$56.9K | 1.65% | 14 |
|
|
2020
Q4 | $5.23M | Buy |
+259,283
| New | +$5.23M | 1.9% | 16 |
|